Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Section 3 of 6

Product information and disease description

297 evidence topics · 146 sources

Product description

Phase of product development

Himalayas-1 registry status and dates
Registry fieldQuoted record
Overall status“Recruiting”
Study start (actual)“2026-08-03”
Primary completion (estimated)“2028-03”
Study completion (estimated)“2030-09”
Expedited program designations

No evidence found.

Regulatory status

No evidence found.

Launch

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Pharmaceutical form and unit strengths

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS classification

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
Pharmacokinetics
Preclinical solubility, oral bioavailability, and half-life
PropertyRinzimetostat
Solubility“11.7 mg/ml”
Mouse oral bioavailability“64%”
Mouse half-life, oral“3-5 hr PO”
Mouse half-life, intravenous“2.5 hr IV”
Clinical half-life“~20 hrs”
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Rinzimetostat
Effects of Rinzimetostat on other drugs
Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Darolutamide: wholesale acquisition cost filing with the California Department of Health Care Access and Information
FieldQuoted record
Manufacturer name“Bayer”
National drug code“50419039501”
Drug product description“Nubeqa 300 mg tab 120 count”
WAC effective date“2026-01-01T00:00:00”
WAC increase amount (USD)“847.20”
WAC after increase (USD)“15100.80”
Effect of Rinzimetostat on quality measures
Product comparison
Mevrometostat plus enzalutamide: MEVPRO-1 and MEVPRO-2 phase 3 designs

“MEVPRO-1 ( NCT06551324 ) is an open-label, phase III trial which will evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Randomization will be stratified by previous docetaxel in the metastatic castration-sensitive prostate cancer (mCSPC) setting, physician’s choice of comparator (prespecified prior to randomization and will remain consistent throughout the study), and presence of hepatic metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“MEVPRO-2 ( NCT06629779 ) is a double-blind, placebo-controlled, phase III trial that will evaluate mevrometostat plus enzalutamide versus enzalutamide alone in adult patients with mCRPC who are treatment-naïve” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary efficacy endpoint for both MEVPRO-1 and MEVPRO-2 is rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by BICR. OS (alpha protected) is a key secondary endpoint in both studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There will be no interim analysis for the primary endpoint (rPFS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Company benchmark comparison: landmark rPFS and safety versus mevrometostat after abiraterone
RegimenMedian follow-upMonth 3 rPFSMonth 4 rPFSMonth 5 rPFSGrade 3 or higher TRAEsDose reductions / discontinuations
Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14)“9.2” months“92%”“92%”“84%”“36%”“7% / 7%”
Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41)“11.7” months“92%”“86%”“80%”“49%”“37% / 2%”
Enzalutamide monotherapy (n=40)“9.0” months“78%”“70%”“60%”“23%”“8% / 5%”
Rinzimetostat 400 mg once daily plus darolutamide (n=18)“4.9” months“93%”“84%”“84%”“6%”“None / 6%”
Company benchmark comparison: serious adverse events and dose modifications versus mevrometostat
MeasureMevrometostat 875 mg twice daily fed plus enzalutamide (n=14)Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41)Rinzimetostat 400 mg once daily plus darolutamide (n=18)
Grade 3 or higher TRAEs“36%”“49%”“6%”
Serious TRAEs“21%”“24%”“None”
Dose reductions“7%”“37%”“None”
Treatment discontinuations“7%”“2%”“6%”

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Distant-stage disease at diagnosis, all prostate cancer
SEER measureQuoted value
Percentage of cases diagnosed at distant stage“9%”
Prevalence of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Modeled U.S. prevalence of metastatic castration-resistant prostate cancer by clinical state, 2009 and 2020
Clinical statePrevalence, 2009Prevalence, 2020 projection
Asymptomatic or minimally symptomatic mCRPC not treated with or not progressed on chemotherapy“6745”View highlighted excerpt for this quote“8320”View highlighted excerpt for this quote
Symptomatic mCRPC not treated with or not progressed on chemotherapy“32,145”View highlighted excerpt for this quote“39,650”View highlighted excerpt for this quote
mCRPC that progressed on or after first-line chemotherapy“23,220”View highlighted excerpt for this quote“28,720”View highlighted excerpt for this quote
Natural history, survival, and mortality
Distant-stage five-year relative survival, all metastatic prostate cancer
SEER measureQuoted value
Distant-stage five-year relative survival“40.1%”
Pathophysiology
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Economic impact of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide on families
Economic impact of diagnostic testing
Cost per PSMA PET scan used in a United States model

Approaches to treatment

Current treatment options and standard of care
Androgen deprivation therapy
Androgen receptor pathway inhibitors
Taxane and platinum chemotherapy
Cabazitaxel versus a second androgen receptor pathway inhibitor after docetaxel: CARD
OutcomeCabazitaxel plus prednisone or prednisolone plus G-CSFAbiraterone plus prednisone or prednisolone, or enzalutamide
Median rPFS, months (95% CI)“8.0 (5.7 to 9.2)”“3.7 (2.8 to 5.1)”
rPFS hazard ratio (95% CI)“0.54 (0.40 to 0.73)”Not applicable
Median OS, months (95% CI)“13.6 [11.5; 17.5]”“11.0 [9.2; 12.9]”
OS hazard ratio (95% CI)“0.64 [0.46; 0.89]”Not applicable
PARP inhibitors
Olaparib monotherapy: PROfound efficacy, cohort A
OutcomeOlaparib (n=162)Enzalutamide or abiraterone acetate (n=83)
Median rPFS, months (95% CI)“7.4 (6.2, 9.3)”“3.6 (1.9, 3.7)”
rPFS hazard ratio (95% CI)“0.34 (0.25, 0.47)”Not applicable
Median OS, months (95% CI)“19.1 (17.4, 23.4)”“14.7 (11.9, 18.8)”
OS hazard ratio (95% CI)“0.69 (0.50, 0.97)”Not applicable
Rucaparib: TRITON3 efficacy, BRCA-mutated subgroup
OutcomeRucaparib (N=201)Androgen receptor pathway inhibitor or docetaxel (N=101)
Median rPFS, months (95% CI)“11.2 (9.2-13.8)”“6.4 (5.4-8.3)”
rPFS hazard ratio (95% CI)“0.50 (0.36, 0.69)”Not applicable
Median OS, months (95% CI)“23.2 (19.1, 25.2)”“21.2 (18.0, 23.1)”
OS hazard ratio (95% CI)“0.91 (0.68, 1.20)”Not applicable
Overall response rate, % (95% CI)“45.1 (34.1, 56.5)”“17.1 (7.2, 32.1)”
First-line combination: talazoparib with enzalutamide
Outcome (TALAPRO-2, HRR gene-mutated)Talazoparib with enzalutamide (N=200)Placebo with enzalutamide (N=199)
Median rPFS by BICR, months (95% CI)“NR (21.9, NR)”“13.8 (11.0, 16.7)”
rPFS hazard ratio (95% CI)“0.45 (0.33, 0.61)”Not applicable
Median OS, months (95% CI)“45.1 (35.4, NR)”“31.1 (27.3, 35.4)”
OS hazard ratio (95% CI)“0.62 (0.48, 0.81)”Not applicable
PSMA-targeted radioligand therapy
Taxane-naive disease after one ARPI: efficacy versus a change in ARPI
OutcomeLutetium Lu 177 vipivotide tetraxetanChange in ARPIHazard ratio (95% CI)
Radiographic progression-free survival, median months (95% CI)“9.3 (7, NE)”“5.6 (4, 6)”“0.41 (0.29, 0.56)”
Overall survival, median months (95% CI)“24.5 (19.5, 28.9)”“23.1 (19.6, 25.5)”“0.91 (0.72, 1.14)”
Disease after ARPI and taxane chemotherapy: overall survival versus best standard of care
OutcomeLutetium Lu 177 vipivotide tetraxetan plus best standard of careBest standard of careHazard ratio (95% CI)
Overall survival, median months (95% CI)“15.3 (14.2, 16.9)”“11.3 (9.8, 13.5)”“0.62 (0.52, 0.74)”
Alpha-emitting radiopharmaceuticals
Symptomatic bone-metastatic disease: overall survival versus placebo
AnalysisRadium Ra 223 dichloride, median months (95% CI)Placebo, median months (95% CI)Hazard ratio (95% CI)
Interim analysis“14.0 (12.1, 15.8)”“11.2 (9.0, 13.2)”“0.695 (0.552, 0.875)”
Updated analysis“14.9 (13.9, 16.1)”“11.3 (10.4, 12.8)”“0.695 (0.581, 0.832)”
Autologous cellular immunotherapy
Immune checkpoint inhibitors
MSI-H or dMMR solid tumors: objective response in prostate cancer
Tumor typePatientsObjective response, n (%)95% CIDuration of response, months
Prostate cancer“8”“1 (13%)”“(0%, 53%)”“24.5+”
Bone-targeted agents
Zoledronic acid versus placebo in metastatic prostate cancer
StudyPatients with a skeletal-related event, zoledronic acid 4 mgPatients with a skeletal-related event, placeboMedian days to first skeletal-related event, zoledronic acid 4 mgMedian days to first skeletal-related event, placeboHazard ratio for first skeletal-related event (95% CI)
Prostate cancer study“33%”“44%”“Not Reached”“321”“0.67 (0.49, 0.91)”
Limitations of current therapies
Summary
  • All patients treated for mCRPC eventually progress. The EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, citing cross-resistance that it extends from abiraterone to apalutamide and darolutamide.
  • Activity of a second ARPI is limited. In a randomized crossover trial, PSA responses to second-line therapy occurred in 26 of 73 participants (36%) receiving enzalutamide and 3 of 75 (4%) receiving abiraterone. In a single-arm study of enzalutamide after at least 24 weeks of abiraterone, median radiographic progression-free survival (rPFS) was 8.1 months and the unconfirmed PSA response rate was 27% (48 of 181). In PLATO, adding abiraterone after PSA progression on enzalutamide did not prolong progression-free survival (5.7 vs 5.6 months; HR, 0.83; 95% CI, 0.61 to 1.12).
  • In the control arms of randomized trials, median rPFS with a second ARPI was 3.7 months in CARD (after docetaxel), 3.6 months in PROfound cohort A (homologous recombination repair gene alterations), 4.5 months in the TRITON3 BRCA subgroup, and 5.59 months in PSMAfore (taxane-naive, third data cut-off), where 17% had a confirmed PSA decline of at least 50%. These figures are cross-trial. The PSMAfore investigators stated that a change in ARPI “has lesser clinical efficacy than taxanes”.
  • Second ARPIs are nonetheless common in practice. In Medicare claims, novel hormonal therapy followed by a different novel hormonal therapy was the most common first- to second-line sequence (33%), only 28% of men starting first-line novel hormonal therapy later received a different class, and 22% received no life-prolonging therapy after mCRPC diagnosis.
  • Taxane chemotherapy carries toxicity: the cabazitaxel label reports serious adverse reactions in 39% of recipients and neutropenic deaths, and in CARD treatment discontinuations for adverse reactions occurred in 20% of cabazitaxel recipients and 8% of those receiving abiraterone or enzalutamide. In TROPIC, grade 3 or higher neutropenia occurred in 82% of cabazitaxel recipients.
  • PSMA-targeted radioligand therapy requires PSMA-positive disease on PET imaging and delivery by providers licensed to handle radiopharmaceuticals; in VISION, 126 screened participants (12.6%) did not meet PSMA imaging criteria. In PSMAfore, median overall survival was 24.5 months with lutetium Lu 177 vipivotide tetraxetan and 23.1 months with a change in ARPI (HR, 0.91; 95% CI, 0.72 to 1.14); the publication reported crossover in 134 of 234 participants (57%) randomized to ARPI change, which “may have confounded” the overall survival analysis, and the label reports crossover in 141 participants (60%).
  • Biomarker-directed therapies apply to subsets. Alterations in BRCA2, BRCA1, or ATM were found in 29 of 150 metastatic biopsies (19.3%), rucaparib is labeled only for BRCA-mutated disease, and in the TRITON3 ATM subgroup the rPFS hazard ratio was 0.95 (95% CI, 0.59 to 1.52). First-line PARP inhibitor combinations are recommended only for patients who did not previously receive an ARPI, and the olaparib-abiraterone trial excluded prior abiraterone. Microsatellite instability-high or mismatch repair-deficient disease was found in 32 of 1033 patients (3.1%); pembrolizumab produced a response in 1 of 8 patients with prostate cancer in the tumor-agnostic label, and objective response rates of 5% and 3% in PD-L1-positive and PD-L1-negative cohorts after docetaxel and endocrine therapy.
  • Other options have restricted populations: radium-223 is labeled for symptomatic bone metastases without known visceral disease, is not recommended with abiraterone plus prednisone because of more fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%), and caused bone marrow failure or ongoing pancytopenia in 2% of recipients. The sipuleucel-T trial excluded visceral metastases and moderate to severe cancer pain; each of its 3 doses requires leukapheresis, and it did not significantly prolong time to disease progression in any phase 3 study. Bisphosphonates have shown no survival benefit in any prospective trial, and overall survival was similar with denosumab and zoledronic acid.
Place in treatment, anticipated use, and care setting
Summary

Rinzimetostat is investigational; ORIC has not submitted for or obtained regulatory approval for any product candidate. Himalayas-1 (NCT07723248) is a global, randomized, open-label phase 3 trial of rinzimetostat plus darolutamide compared with a prespecified physician’s choice of an ARPI or docetaxel in approximately 600 participants with mCRPC previously treated with abiraterone. The trial requires disease progression on abiraterone in the metastatic castration-sensitive or first-line mCRPC setting, permits docetaxel for castration-sensitive disease, and excludes prior cytotoxic chemotherapy otherwise, radioligand therapy, and apalutamide, darolutamide, or enzalutamide; it was recruiting with an actual start of 2026-08-03 and an estimated primary completion of 2028-03. The proposed position is therefore after abiraterone and before chemotherapy, radioligand therapy, or a second ARPI for castration-resistant disease. A separate phase 3 trial evaluates another PRC2 inhibitor, mevrometostat, plus enzalutamide against physician’s choice of enzalutamide or docetaxel in mCRPC after at least 12 weeks of abiraterone.

Both components of the regimen are oral: participants are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily, while the docetaxel control is given at 75 mg/m2 intravenously every 21 days for up to 10 cycles. The darolutamide label lists non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer (alone or with docetaxel), without mCRPC, and requires a concurrent gonadotropin-releasing hormone agonist or antagonist or prior bilateral orchiectomy.

ORIC estimated the U.S. population at approximately 17,000 men per year with mCRPC previously treated with abiraterone and an addressable market of more than $3.5 billion, reported that abiraterone, the leading ARPI, has maintained more than 50% market share of new prescriptions over the last five years, and stated that this market “lacks oral, well-tolerated therapies with meaningful efficacy”. ORIC is also exploring rinzimetostat in other populations, including post-AR inhibitor mCRPC, and lists a second phase 3 trial (Himalayas-2) with apalutamide. These are company statements that are not peer reviewed.

The regimen pairs rinzimetostat with a second ARPI in a setting where the EAU guideline advises avoiding sequencing of androgen receptor-targeted agents, recommends chemotherapy after an ARPI, and states that an ARPI-ARPI sequence “should never be the preferred option”. In U.S. practice, a second ARPI is nonetheless the most frequent choice: 459 of 804 ARPI-experienced patients with mCRPC (57.1%) received another ARPI and 192 (23.9%) chemotherapy; among 1,519 Medicare patients with prior novel hormonal therapy, 70% received novel hormonal therapy as first-line mCRPC treatment, 7% chemotherapy, and 13% no subsequent life-prolonging therapy. In another real-world cohort, 48.4% received a sequential ARPI and 35% docetaxel as index therapy, abiraterone followed by docetaxel (16.1%) and abiraterone followed by enzalutamide (10.9%) were the most common sequences, and taxane use was 42% to 46% with ECOG performance status 0 to 1 and 29% with ECOG 2 or higher. The initial ARPI is increasingly given before castration resistance: in pre-mCRPC settings in 82.6% of patients in that cohort, and as ARPI-only treatment before mCRPC diagnosis in 34.8% of a U.S. cohort in 2023, compared with 10.3% in 2018.

US real-world treatment after a prior androgen receptor pathway inhibitor
Heterogeneity of treatment effect
Phase 1b landmark radiographic progression-free survival by prior therapy
Cohort (rinzimetostat 400 mg once daily plus darolutamide)Landmark rPFS at 3, 4, and 5 monthsMedian follow-up
Previously treated with abiraterone“93%, 84%, and 84% at 3, 4, and 5 months”“4.9 months”
Previously treated with AR inhibitors“93%, 85%, and 85% at 3, 4, and 5 months”“4.8 months”
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy